Spots Global Cancer Trial Database for Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
Official Title: Phase I and Pharmacokinetic Study of E7820 After Oral Administration to Patients With Malignancy
Study ID: NCT00078637
Interventions
Study Description
Brief Summary: This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, San Antonio, Texas, United States
Contact Details
Name: Jantien Wanders, M.D.
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
